EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Design of a potent and selective dual JAK1/TYK2 inhibitor

Oscar Mammoliti, Christel Menet, Céline Cottereaux, Javier Blanc, Ann De Blieck, Ghjuvanni Coti, Raphaël Geney, Line Oste, Koen Ostyn, Adeline Palisse, Evelyne Quinton, Benoit Schmitt und 11 weitere

Bioorganic & Medicinal Chemistry · 2024

DOI: 10.1016/j.bmc.2024.117932 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic & Medicinal Chemistry, 2024. Verfasst von Oscar Mammoliti und 22 weiteren Autor:innen. Beteiligte Einrichtung: Galapagos NV, Generaal De Wittelaan L11, 2800 Mechelen, Belgium. Hauptthemen laut MEDLINE: TYK2 Kinase, Janus Kinase 1, Protein Kinase Inhibitors, Drug Design. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Galápagos.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Janus kinase (JAK) inhibitors have gathered interest as treatments for several inflammatory and autoimmune diseases. The four first marketed inhibitors target JAK1, with varying selectivity towards other JAK family members, but none inhibit tyrosine kinase-2 (TYK2) at clinically relevant doses. TYK2 is required for the signaling of the interleukin (IL)-12 and IL-23 cytokines, which are key to the polarization of TH1 and TH17 cells, respectively; two cell subtypes that play major roles in inflammatory diseases. Herein, we report our effort towards the optimization of a potent and selective dual JAK1/TYK2 inhibitor series starting from a HTS hit. Structural information revealed vectors required to improve both JAK1 and TYK2 potency as well as selectivity towards JAK2. The potent inhibition of both JAK1 (3.5 nM) and TYK2 (5.7 nM) in biochemical assays by our optimized lead compound, as well as its notable selectivity against JAK2, were confirmed in cellular and whole blood assays. Inhibition of TYK2 by the lead compound was demonstrated by dose-dependent efficacy in an IL-23-induced psoriasis-like inflammation mouse model.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TYK2 KinaseJanus Kinase 1Protein Kinase InhibitorsDrug DesignAnimalsHumansMiceStructure-Activity RelationshipInterleukin-23Molecular StructureDose-Response Relationship, DrugPsoriasis

Stichwörter der Autor:innen

Autoimmune diseaseHigh-throughput screeningInflammatory diseaseJanus kinaseSelective inhibitorTyrosine kinase

Substanzen

TYK2 KinaseJanus Kinase 1Protein Kinase InhibitorsInterleukin-23JAK1 protein, humanTYK2 protein, human

Autor:innen und Institutionen

  • Galapagos NV, Generaal De Wittelaan L11, 2800 Mechelen, Belgium.
  • Galapagos SASU, 102 Avenue Gaston Roussel, 93230 Romainville, France.
  • Galapagos NV, Generaal De Wittelaan L11, 2800 Mechelen, Belgium. Electronic address: caroline.joannesse@glpg.com.

Förderung

  • Galápagos

Zitieren

APA

Mammoliti, O., Menet, C., Cottereaux, C., Blanc, J., De Blieck, A., Coti, G., Geney, R., Oste, L., Ostyn, K., Palisse, A., Quinton, E., Schmitt, B., Borgonovi, M., Parent, I., Jagerschmidt, C., De Vos, S., Vayssiere, B., López-Ramos, M., Shoji, K., …, & Joannesse, C. (2024). Design of a potent and selective dual JAK1/TYK2 inhibitor. Bioorganic & Medicinal Chemistry. https://doi.org/10.1016/j.bmc.2024.117932

Vancouver

Mammoliti O, Menet C, Cottereaux C, Blanc J, De Blieck A, Coti G, et al. Design of a potent and selective dual JAK1/TYK2 inhibitor. Bioorganic & Medicinal Chemistry. 2024. doi:10.1016/j.bmc.2024.117932

BibTeX
@article{Mammoliti2024,
  author = {Mammoliti, Oscar and Menet, Christel and Cottereaux, Céline and Blanc, Javier and De Blieck, Ann and Coti, Ghjuvanni and Geney, Raphaël and Oste, Line and Ostyn, Koen and Palisse, Adeline and Quinton, Evelyne and Schmitt, Benoit and Borgonovi, Monica and Parent, Isabelle and Jagerschmidt, Catherine and De Vos, Steve and Vayssiere, Béatrice and López-Ramos, Miriam and Shoji, Kenji and Brys, Reginald and Amantini, David and Galien, René and Joannesse, Caroline},
  title = {Design of a potent and selective dual JAK1/TYK2 inhibitor},
  journal = {Bioorganic & Medicinal Chemistry},
  year = {2024},
  doi = {10.1016/j.bmc.2024.117932}
}
Kostenlos starten →